arrow
A

Alfredo Ponce-de-León

instituto nacional de ciencias médicas y nutricion salvador zubiran
H指数:52
被引数:2.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Epidemiology and clinical outcomes of filler-related complications among transgender women in Mexico

墨西哥跨性别女性中与填充剂相关的并发症的流行病学和临床结局

2026-10-140
OAAI
Clinical characteristics of patients with extrapulmonary and disseminated tuberculosis: a 23-year retrospective cohort study in non-HIV patients without pharmacological immunosuppression

非HIV、无药物免疫抑制患者的肺外及播散性结核的临床特征:一项为期23年的回顾性队列研究

2026-09-090
OAAI
Granulomatous Liver Disease in a Referral Center in Mexico City

墨西哥城一家转诊中心报告的肉芽肿性肝病

2025-08-300
OAAI
Distinct Clinical Features of Extrapulmonary and Disseminated Tuberculosis in HIV- and Non-HIV-Associated Immunosuppression: A Retrospective Cohort Study

HIV相关与非HIV相关免疫抑制患者中,肺外结核和播散性结核的特异性临床特征:一项回顾性队列研究

2025-04-250
OA
Rapid Detection of Carbapenemases Using NG-Test® CARBA 5 in Positive Blood Cultures: A Diagnostic Test Study
2024-11-202
OA
Nirmatrelvir/ritonavir and remdesivir against symptomatic treatment in high-risk COVID-19 outpatients to prevent hospitalization or death during the Omicron era: a propensity score-matched study

Nirmatrelvir/利托那韦和remdesivir对抗高危新型冠状病毒肺炎门诊患者的对症治疗,以防止Omicron时代的住院或死亡: 倾向评分匹配研究

2024-03-263
OAAI
Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT)
2024-03-050
OAAI
Histoplasmosis Beyond Human Immunodeficiency Virus (HIV): Clinical Characteristics and Outcomes in a Non-HIV Population

人类免疫缺陷病毒 (HIV) 以外的组织胞浆菌病: 非HIV人群的临床特征和结局

2024-02-151
OAAI
Active Surveillance of Antimicrobial Resistance and Carbapenemase-Encoding Genes According to Sites of Care and Age Groups in Mexico: Results from the INVIFAR Network
2023-09-077
OAAI
The burden of antimicrobial resistance in the Americas in 2019: a cross-country systematic analysis

美洲2019年的抗菌素耐药性负担: 跨国系统分析

2023-09-0152
OAAI
Safety and Tolerability of Six Months of Isoniazid Plus Pyridoxine or Three Months of Rifampicin for Tuberculosis among Subjects with Diabetes Mellitus: A Randomized Trial
2023-07-280
OAAI
Predictors of Mortality in Patients with Infections Due to Carbapenem-Resistant Gram-Negative Bacteria

耐碳青霉烯类革兰氏阴性菌感染患者死亡率的预测因素

2023-06-294
OAAI